ARTICLE SUMMARY:
Building new things often calls for flexibility and creative thinking. This is certainly the case when it comes to a company leveraging available medtech regulatory and reimbursement pathways.
I was struck in discussions at the Wilson Sonsini Goodrich & Rosati Medical Device Conference last month (where we unveiled the inaugural issue of MTS Market Pathways) by the diversity of challenges firms face and the need to adapt to circumstances. Solutions to problems can be as complex as designing a novel clinical trial protocol to respond to regulators’ questions, or as seemingly simple as changing a product’s name to support a more tailored and favorable reimbursement policy.
